GlaxoSmithKline on Wednesday raised its earnings outlook for the second consecutive quarter on the back of robust sales of Shingrix, its shingles vaccine, and a strong overall performance in consumer health and vaccines.
Overall sales in the third quarter ro…

Click here to view the original article.